Format

Send to

Choose Destination
Diseases. 2018 Sep 22;6(4). pii: E85. doi: 10.3390/diseases6040085.

Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer.

Author information

1
Department of Chemistry, Colorado State University, Fort Collins, CO 80521, USA. jenna.short@colostate.edu.
2
Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80521, USA. mark.brown@colostate.edu.
3
Department of Chemistry, Colorado State University, Campus Delivery 1872, Fort Collins, CO 80523, USA. melissa.reynolds@colostate.edu.
4
School of Biomedical Engineering, Colorado State University, Fort Collins, CO 80523, USA. melissa.reynolds@colostate.edu.

Abstract

Determination of therapeutic efficacy is a major challenge in developing treatment options for cancer. Prior to in vivo studies, candidate therapeutics are evaluated using cell-based in vitro methods to assess their anti-cancer potential. This review describes the utility and limitations of evaluating therapeutic efficacy using human tumor-derived cell lines. Indicators for therapeutic efficacy using tumor-derived cell lines include cell viability, cell proliferation, colony formation, cytotoxicity, cytostasis, induction of apoptosis, and cell cycle arrest. Cell panel screens, 3D tumor spheroid models, drug-drug/drug-radiation combinatorial analysis, and invasion/migration assays reveal analogous in vitro information. In animal models, cellular assays can assess tumor micro-environment and therapeutic delivery. The utility of tumor-derived cell lines for efficacy determination is manifest in numerous commercially approved drugs that have been applied in clinical management of cancer. Studies reveal most tumor-derived cell lines preserve the genomic signature of the primary tumor source and cell line-based data is highly predictive of subsequent clinical studies. However, cell-based data often disregards natural system components, resulting in cell autonomous outcomes. While 3D cell culture platforms can counter such limitations, they require additional time and cost. Despite the limitations, cell-based methods remain essential in early stages of anti-cancer drug development.

KEYWORDS:

bioassay approaches; in vivo/in vitro correlation; pharmaceutical analysis

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center